Periorificial dermatitis in infants and preschoolers - a narrative review

Anca Chiriac1,2,3, Anca E Chiriac4, Bhushan Madke5

  • 1Department of Dermatology, Nicolina Medical Center, Iasi, Romania.

PubMed

Insights

Periorificial dermatitis (POD) in children is a clinical diagnosis presenting as red papules. Treatment avoids tetracyclines in young children, favoring topical or oral erythromycin.

Area of Science:

  • Dermatology
  • Pediatric Dermatology
  • Inflammatory Skin Diseases

Background:

  • Periorificial dermatitis (POD) is a chronic inflammatory skin condition.
  • It commonly affects women aged 20-40, with differential diagnosis including persistent acne.
  • POD is less frequent in children, and rare in infants and preschoolers.

Purpose of the Study:

  • To conduct a narrative review of periorificial dermatitis in children aged 6 years and younger.
  • To outline diagnostic criteria and clinical presentation in pediatric populations.
  • To review current and emerging treatment strategies for pediatric POD.

Main Methods:

  • Narrative review of existing literature on pediatric periorificial dermatitis.
  • Analysis of clinical presentation, diagnostic challenges, and treatment outcomes.
  • Focus on age-specific considerations, particularly contraindications for certain medications.

Main Results:

  • Diagnosis of POD in children is primarily clinical, characterized by monomorphic erythematous papules.
  • The granulomatous subtype is more prevalent in younger children compared to adults.
  • Key differential diagnoses include atopic dermatitis, seborrheic dermatitis, pediatric rosacea, juvenile acne, and cutaneous sarcoidosis.

Conclusions:

  • Topical metronidazole or erythromycin and oral erythromycin are common treatments for pediatric POD.
  • Tetracyclines are contraindicated in infants and preschoolers due to potential adverse effects on bone and teeth development.
  • Further research, including randomized controlled trials, is needed for optimal management of pediatric POD, with JAK inhibitors showing future promise.